{"protocolSection": {"identificationModule": {"nctId": "NCT01377987", "orgStudyIdInfo": {"id": "2011-P-000049/1"}, "organization": {"fullName": "Brigham and Women's Hospital", "class": "OTHER"}, "briefTitle": "Predicting Successful Sleep Apnea Treatment With Acetazolamide in Heart Failure Patients", "officialTitle": "Physiological Study to Predict Successful Sleep Apnea Treatment With Acetazolamide in Heart Failure Patients", "acronym": "HF-ACZ"}, "statusModule": {"statusVerifiedDate": "2018-05", "overallStatus": "COMPLETED", "expandedAccessInfo": {"hasExpandedAccess": false}, "startDateStruct": {"date": "2011-08"}, "primaryCompletionDateStruct": {"date": "2016-12", "type": "ACTUAL"}, "completionDateStruct": {"date": "2016-12", "type": "ACTUAL"}, "studyFirstSubmitDate": "2011-06-20", "studyFirstSubmitQcDate": "2011-06-20", "studyFirstPostDateStruct": {"date": "2011-06-22", "type": "ESTIMATED"}, "resultsFirstSubmitDate": "2018-04-17", "resultsFirstSubmitQcDate": "2018-05-16", "resultsFirstPostDateStruct": {"date": "2018-06-13", "type": "ACTUAL"}, "lastUpdateSubmitDate": "2018-05-16", "lastUpdatePostDateStruct": {"date": "2018-06-13", "type": "ACTUAL"}}, "sponsorCollaboratorsModule": {"responsibleParty": {"type": "SPONSOR_INVESTIGATOR", "investigatorFullName": "David Andrew Wellman", "investigatorTitle": "Associate Professor of Medicine", "investigatorAffiliation": "Brigham and Women's Hospital"}, "leadSponsor": {"name": "David Andrew Wellman", "class": "OTHER"}, "collaborators": [{"name": "American Heart Association", "class": "OTHER"}, {"name": "National Institutes of Health (NIH)", "class": "NIH"}]}, "oversightModule": {"oversightHasDmc": false}, "descriptionModule": {"briefSummary": "The ultimate goal is to improve our understanding of the pathophysiology and resistance to effective treatment of sleep disordered breathing in patients with heart failure, with a focus on selecting patients that will benefit specifically from acetazolamide treatment.\n\nThe study addresses three primary hypotheses: 1) Acetazolamide treatment will reduce the apnea-hypopnea index and improve markers of heart-failure severity in heart-failure patients with sleep apnea. 2) Acetazolamide will provide the greatest improvement in patients with the most severe ventilatory control instability (strongest chemoreflex response to carbon dioxide; highest loop gain). 3) Acetazolamide will act primarily via stabilizing ventilatory control (reducing loop gain), rather than via improvement to upper airway anatomy, pulmonary congestion, and cardiac function."}, "conditionsModule": {"conditions": ["Heart Failures"]}, "designModule": {"studyType": "INTERVENTIONAL", "phases": ["NA"], "designInfo": {"allocation": "RANDOMIZED", "interventionModel": "CROSSOVER", "primaryPurpose": "BASIC_SCIENCE", "maskingInfo": {"masking": "DOUBLE", "whoMasked": ["PARTICIPANT", "INVESTIGATOR"]}}, "enrollmentInfo": {"count": 29, "type": "ACTUAL"}}, "armsInterventionsModule": {"armGroups": [{"label": "Acetazolamide", "type": "EXPERIMENTAL", "interventionNames": ["Drug: Acetazolamide"]}, {"label": "Sugar pill", "type": "PLACEBO_COMPARATOR", "interventionNames": ["Drug: Placebo"]}], "interventions": [{"type": "DRUG", "name": "Acetazolamide", "description": "4 mg/kg, once daily before bed, for 7 days", "armGroupLabels": ["Acetazolamide"], "otherNames": ["Diamox"]}, {"type": "DRUG", "name": "Placebo", "description": "4 mg/kg, once daily before bed, for 7 days", "armGroupLabels": ["Sugar pill"]}]}, "outcomesModule": {"primaryOutcomes": [{"measure": "The Severity of Sleep Disordered Breathing (Apnea-hypopnea Index, AHI)", "description": "The frequency of apneas and hypopneas (apnea-hypopnea index) was assessed. The primary measure was the value for non-REM supine sleep. A higher value indicates more severe sleep apnea. A value above 15 indicates the presence of moderate-to-severe sleep apnea.", "timeFrame": "1 week"}], "secondaryOutcomes": [{"measure": "Ventilatory Chemoreflex Sensitivity, \"Loop Gain\" Using Carbon Dioxide Pulses", "description": "Chemoreflex \"loop gain\" was assessed according to Sands SA et al AJRCCM 2017 Jan 15;195(2):237-246. Loop gain is a unitless ratio measure that describes the magnitude of the increase in ventilation that occurs in response to a prior reduction in ventilation (\"disturbance\") and has units of L/min per L/min. A larger value indicates a more sensitive and unstable control system predisposing to oscillatory breathing. Loop gain was measured on the time scale of 1 min (i.e. response to a 1 cycle/min sinusoidal disturbance, referred to as \"LG1\"). The procedure involved brief administration of 7% carbon dioxide in air for 0.5 min (\"pulses\"); tests were repeated every 3 min for 30 min while measuring ventilation and carbon dioxide levels at the nose with patients awake and supine.\n\nmeasured using 0.5 min pulses of carbon dioxide.", "timeFrame": "1 week"}, {"measure": "Sympathetic Activity (Urinary Norepinephrine)", "description": "Urinary norepinephrine levels overnight", "timeFrame": "1 week"}, {"measure": "Left-atrial Volume", "description": "Left-atrial volume index, echocardiography, bi-plane method. Lower values were considered a favorable outcome. We considered values \u226428 mL/m\\^2 to indicate normal left atrial volume. Values indicating graded left atrial enlargement were described as follows: mild (29-33 mL/m\\^2), moderate (34-39 mL/m\\^2), severe (\u226540 mL/m\\^2).", "timeFrame": "1 week"}, {"measure": "Brain Natriuretic Peptide (NT-proBNP)", "description": "Brain natriuretic peptide (NT-proBNP) in morning", "timeFrame": "1 week"}, {"measure": "Pittsburgh Sleep Quality Index", "description": "Pittsburgh Sleep Quality Index is a measure of self-reported sleep quality containing 19 questions that make up 7 component scores that are added to provide a total score. Total scores range from 0-21 (units on a scale) with higher scores representing reduced sleep quality. A score of 5 or more is interpreted as reduced sleep quality. The total score is reported.", "timeFrame": "1 week"}]}, "eligibilityModule": {"eligibilityCriteria": "Inclusion Criteria (Heart failure patients)\n\n* Left ventricular ejection fraction (EF) \\<50%, or heart failure with preserved EF\n* Age 18-89\n\nExclusion Criteria:\n\n* severe obstructive respiratory disease\n* unstable heart failure status\n* recent use of positive airway pressure therapy\n* current use of opioids, benzodiazepines\n* severe kidney disease\n* severe anemia", "healthyVolunteers": false, "sex": "ALL", "minimumAge": "18 Years", "maximumAge": "89 Years", "stdAges": ["ADULT", "OLDER_ADULT"]}, "contactsLocationsModule": {"overallOfficials": [{"name": "Andrew Wellman, MD, PhD", "affiliation": "Brigham and Women's Hospital", "role": "PRINCIPAL_INVESTIGATOR"}, {"name": "Atul Malhotra, MD", "affiliation": "Brigham and Women's Hospital", "role": "PRINCIPAL_INVESTIGATOR"}], "locations": [{"facility": "Brigham and Women's Hospital", "city": "Boston", "state": "Massachusetts", "zip": "02115", "country": "United States", "geoPoint": {"lat": 42.35843, "lon": -71.05977}}]}}, "resultsSection": {"participantFlowModule": {"groups": [{"id": "FG000", "title": "Acetazolamide First, Then Placebo", "description": "Acetazolamide: 4 mg/kg, once daily before bed, for 7 days\n\n1 week washout Placebo: 4 mg/kg, once daily before bed, for 7 days"}, {"id": "FG001", "title": "Placebo First, Then Acetazolamide", "description": "Placebo: 4 mg/kg, once daily before bed, for 7 days\n\n1 week washout Acetazolamide: 4 mg/kg, once daily before bed, for 7 days"}], "periods": [{"title": "First Intervention (7 Days)", "milestones": [{"type": "STARTED", "achievements": [{"groupId": "FG000", "numSubjects": "14"}, {"groupId": "FG001", "numSubjects": "15"}]}, {"type": "COMPLETED", "achievements": [{"groupId": "FG000", "numSubjects": "14"}, {"groupId": "FG001", "numSubjects": "15"}]}, {"type": "NOT COMPLETED", "achievements": [{"groupId": "FG000", "numSubjects": "0"}, {"groupId": "FG001", "numSubjects": "0"}]}]}, {"title": "Washout (7 Days)", "milestones": [{"type": "STARTED", "achievements": [{"groupId": "FG000", "numSubjects": "14"}, {"groupId": "FG001", "numSubjects": "15"}]}, {"type": "COMPLETED", "achievements": [{"groupId": "FG000", "numSubjects": "13"}, {"groupId": "FG001", "numSubjects": "14"}]}, {"type": "NOT COMPLETED", "achievements": [{"groupId": "FG000", "numSubjects": "1"}, {"groupId": "FG001", "numSubjects": "1"}]}], "dropWithdraws": [{"type": "Withdrawal by Subject", "reasons": [{"groupId": "FG000", "numSubjects": "1"}, {"groupId": "FG001", "numSubjects": "1"}]}]}, {"title": "Second Intervention (7 Days)", "milestones": [{"type": "STARTED", "achievements": [{"groupId": "FG000", "numSubjects": "13"}, {"groupId": "FG001", "numSubjects": "14"}]}, {"type": "COMPLETED", "achievements": [{"groupId": "FG000", "numSubjects": "13"}, {"groupId": "FG001", "numSubjects": "14"}]}, {"type": "NOT COMPLETED", "achievements": [{"groupId": "FG000", "numSubjects": "0"}, {"groupId": "FG001", "numSubjects": "0"}]}]}]}, "baselineCharacteristicsModule": {"populationDescription": "All patients randomized", "groups": [{"id": "BG000", "title": "All Patients", "description": "All patients randomized"}], "denoms": [{"units": "Participants", "counts": [{"groupId": "BG000", "value": "29"}]}], "measures": [{"title": "Age, Continuous", "paramType": "MEAN", "dispersionType": "STANDARD_DEVIATION", "unitOfMeasure": "years", "classes": [{"categories": [{"measurements": [{"groupId": "BG000", "value": "60", "spread": "13"}]}]}]}, {"title": "Sex: Female, Male", "paramType": "COUNT_OF_PARTICIPANTS", "unitOfMeasure": "Participants", "classes": [{"categories": [{"title": "Female", "measurements": [{"groupId": "BG000", "value": "3"}]}, {"title": "Male", "measurements": [{"groupId": "BG000", "value": "26"}]}]}]}, {"title": "Race (NIH/OMB)", "paramType": "COUNT_OF_PARTICIPANTS", "unitOfMeasure": "Participants", "classes": [{"categories": [{"title": "American Indian or Alaska Native", "measurements": [{"groupId": "BG000", "value": "0"}]}, {"title": "Asian", "measurements": [{"groupId": "BG000", "value": "0"}]}, {"title": "Native Hawaiian or Other Pacific Islander", "measurements": [{"groupId": "BG000", "value": "0"}]}, {"title": "Black or African American", "measurements": [{"groupId": "BG000", "value": "1"}]}, {"title": "White", "measurements": [{"groupId": "BG000", "value": "28"}]}, {"title": "More than one race", "measurements": [{"groupId": "BG000", "value": "0"}]}, {"title": "Unknown or Not Reported", "measurements": [{"groupId": "BG000", "value": "0"}]}]}]}]}, "outcomeMeasuresModule": {"outcomeMeasures": [{"type": "PRIMARY", "title": "The Severity of Sleep Disordered Breathing (Apnea-hypopnea Index, AHI)", "description": "The frequency of apneas and hypopneas (apnea-hypopnea index) was assessed. The primary measure was the value for non-REM supine sleep. A higher value indicates more severe sleep apnea. A value above 15 indicates the presence of moderate-to-severe sleep apnea.", "populationDescription": "All participants who were randomized and completed the relevant study arm. Data are for non-REM supine sleep.", "reportingStatus": "POSTED", "paramType": "MEAN", "dispersionType": "Standard Deviation", "unitOfMeasure": "events per hour", "timeFrame": "1 week", "groups": [{"id": "OG000", "title": "Acetazolamide", "description": "Acetazolamide (active arm)"}, {"id": "OG001", "title": "Placebo", "description": "Placebo arm"}], "denoms": [{"units": "Participants", "counts": [{"groupId": "OG000", "value": "28"}, {"groupId": "OG001", "value": "28"}]}], "classes": [{"title": "All participants", "denoms": [{"units": "Participants", "counts": [{"groupId": "OG000", "value": "28"}, {"groupId": "OG001", "value": "28"}]}], "categories": [{"measurements": [{"groupId": "OG000", "value": "26.3", "spread": "22.7"}, {"groupId": "OG001", "value": "36.1", "spread": "27.8"}]}]}, {"title": "Patients with sleep apnea", "denoms": [{"units": "Participants", "counts": [{"groupId": "OG000", "value": "22"}, {"groupId": "OG001", "value": "22"}]}], "categories": [{"measurements": [{"groupId": "OG000", "value": "32.3", "spread": "22.1"}, {"groupId": "OG001", "value": "44.6", "spread": "25.3"}]}]}]}, {"type": "SECONDARY", "title": "Ventilatory Chemoreflex Sensitivity, \"Loop Gain\" Using Carbon Dioxide Pulses", "description": "Chemoreflex \"loop gain\" was assessed according to Sands SA et al AJRCCM 2017 Jan 15;195(2):237-246. Loop gain is a unitless ratio measure that describes the magnitude of the increase in ventilation that occurs in response to a prior reduction in ventilation (\"disturbance\") and has units of L/min per L/min. A larger value indicates a more sensitive and unstable control system predisposing to oscillatory breathing. Loop gain was measured on the time scale of 1 min (i.e. response to a 1 cycle/min sinusoidal disturbance, referred to as \"LG1\"). The procedure involved brief administration of 7% carbon dioxide in air for 0.5 min (\"pulses\"); tests were repeated every 3 min for 30 min while measuring ventilation and carbon dioxide levels at the nose with patients awake and supine.\n\nmeasured using 0.5 min pulses of carbon dioxide.", "populationDescription": "All participants who completed the relevant arm. Morning data are reported.", "reportingStatus": "POSTED", "paramType": "MEAN", "dispersionType": "Standard Deviation", "unitOfMeasure": "unitless", "timeFrame": "1 week", "groups": [{"id": "OG000", "title": "Acetazolamide", "description": "Acetazolamide (active arm)"}, {"id": "OG001", "title": "Placebo", "description": "Placebo arm"}], "denoms": [{"units": "Participants", "counts": [{"groupId": "OG000", "value": "28"}, {"groupId": "OG001", "value": "28"}]}], "classes": [{"categories": [{"measurements": [{"groupId": "OG000", "value": "0.40", "spread": "0.16"}, {"groupId": "OG001", "value": "0.49", "spread": "0.14"}]}]}]}, {"type": "SECONDARY", "title": "Sympathetic Activity (Urinary Norepinephrine)", "description": "Urinary norepinephrine levels overnight", "populationDescription": "All participants who completed the relevant study arm", "reportingStatus": "POSTED", "paramType": "MEAN", "dispersionType": "Standard Deviation", "unitOfMeasure": "ug/g-creatinine", "timeFrame": "1 week", "groups": [{"id": "OG000", "title": "Acetazolamide", "description": "Acetazolamide (active arm)"}, {"id": "OG001", "title": "Placebo", "description": "Placebo arm"}], "denoms": [{"units": "Participants", "counts": [{"groupId": "OG000", "value": "28"}, {"groupId": "OG001", "value": "28"}]}], "classes": [{"categories": [{"measurements": [{"groupId": "OG000", "value": "40.8", "spread": "23.6"}, {"groupId": "OG001", "value": "35.0", "spread": "17.3"}]}]}]}, {"type": "SECONDARY", "title": "Left-atrial Volume", "description": "Left-atrial volume index, echocardiography, bi-plane method. Lower values were considered a favorable outcome. We considered values \u226428 mL/m\\^2 to indicate normal left atrial volume. Values indicating graded left atrial enlargement were described as follows: mild (29-33 mL/m\\^2), moderate (34-39 mL/m\\^2), severe (\u226540 mL/m\\^2).", "populationDescription": "echocardiography could not be performed on one study due to rescheduling issues", "reportingStatus": "POSTED", "paramType": "MEAN", "dispersionType": "Standard Deviation", "unitOfMeasure": "mL/m^2", "timeFrame": "1 week", "groups": [{"id": "OG000", "title": "Acetazolamide", "description": "Acetazolamide (active arm)"}, {"id": "OG001", "title": "Placebo", "description": "Placebo arm"}], "denoms": [{"units": "Participants", "counts": [{"groupId": "OG000", "value": "27"}, {"groupId": "OG001", "value": "28"}]}], "classes": [{"categories": [{"measurements": [{"groupId": "OG000", "value": "34.3", "spread": "12.1"}, {"groupId": "OG001", "value": "40.0", "spread": "13.5"}]}]}]}, {"type": "SECONDARY", "title": "Brain Natriuretic Peptide (NT-proBNP)", "description": "Brain natriuretic peptide (NT-proBNP) in morning", "populationDescription": "All participants who completed the relevant arm", "reportingStatus": "POSTED", "paramType": "MEAN", "dispersionType": "Standard Deviation", "unitOfMeasure": "pg/ml", "timeFrame": "1 week", "groups": [{"id": "OG000", "title": "Acetazolamide", "description": "Acetazolamide (active arm)"}, {"id": "OG001", "title": "Placebo", "description": "Placebo arm"}], "denoms": [{"units": "Participants", "counts": [{"groupId": "OG000", "value": "28"}, {"groupId": "OG001", "value": "28"}]}], "classes": [{"categories": [{"measurements": [{"groupId": "OG000", "value": "919", "spread": "1320"}, {"groupId": "OG001", "value": "932", "spread": "1403"}]}]}]}, {"type": "SECONDARY", "title": "Pittsburgh Sleep Quality Index", "description": "Pittsburgh Sleep Quality Index is a measure of self-reported sleep quality containing 19 questions that make up 7 component scores that are added to provide a total score. Total scores range from 0-21 (units on a scale) with higher scores representing reduced sleep quality. A score of 5 or more is interpreted as reduced sleep quality. The total score is reported.", "populationDescription": "All participants who participated in the relevant study arm.", "reportingStatus": "POSTED", "paramType": "MEAN", "dispersionType": "Standard Deviation", "unitOfMeasure": "units on a scale", "timeFrame": "1 week", "groups": [{"id": "OG000", "title": "Acetazolamide", "description": "Acetazolamide (active arm)"}, {"id": "OG001", "title": "Placebo", "description": "Placebo arm"}], "denoms": [{"units": "Participants", "counts": [{"groupId": "OG000", "value": "28"}, {"groupId": "OG001", "value": "28"}]}], "classes": [{"categories": [{"measurements": [{"groupId": "OG000", "value": "6.7", "spread": "3.6"}, {"groupId": "OG001", "value": "7.5", "spread": "3.8"}]}]}]}]}, "adverseEventsModule": {"frequencyThreshold": "0", "eventGroups": [{"id": "EG000", "title": "Acetazolamide", "description": "Acetazolamide (active arm)", "deathsNumAffected": 0, "deathsNumAtRisk": 28, "seriousNumAffected": 0, "seriousNumAtRisk": 28, "otherNumAffected": 17, "otherNumAtRisk": 28}, {"id": "EG001", "title": "Placebo", "description": "Placebo arm", "deathsNumAffected": 0, "deathsNumAtRisk": 28, "seriousNumAffected": 0, "seriousNumAtRisk": 28, "otherNumAffected": 6, "otherNumAtRisk": 28}], "otherEvents": [{"term": "Fall without injury", "organSystem": "General disorders", "assessmentType": "SYSTEMATIC_ASSESSMENT", "notes": "Fall without injury during 7 days using study medication", "stats": [{"groupId": "EG000", "numEvents": 1, "numAffected": 1, "numAtRisk": 28}, {"groupId": "EG001", "numEvents": 0, "numAffected": 0, "numAtRisk": 28}]}, {"term": "Nocturia", "organSystem": "Renal and urinary disorders", "assessmentType": "SYSTEMATIC_ASSESSMENT", "notes": "Self-reported incident nocturia during 7 days using study medication", "stats": [{"groupId": "EG000", "numEvents": 12, "numAffected": 12, "numAtRisk": 28}, {"groupId": "EG001", "numEvents": 1, "numAffected": 1, "numAtRisk": 28}]}, {"term": "Taste Disturbance", "organSystem": "Metabolism and nutrition disorders", "assessmentType": "SYSTEMATIC_ASSESSMENT", "notes": "Self-reported incident taste disturbances during 7 days using study medication", "stats": [{"groupId": "EG000", "numEvents": 4, "numAffected": 4, "numAtRisk": 28}, {"groupId": "EG001", "numEvents": 0, "numAffected": 0, "numAtRisk": 28}]}, {"term": "Paresthesias", "organSystem": "Nervous system disorders", "assessmentType": "SYSTEMATIC_ASSESSMENT", "notes": "Self-reported incident paresthesias during 7 days using study medication", "stats": [{"groupId": "EG000", "numEvents": 5, "numAffected": 5, "numAtRisk": 28}, {"groupId": "EG001", "numEvents": 0, "numAffected": 0, "numAtRisk": 28}]}, {"term": "Fatigue", "organSystem": "General disorders", "assessmentType": "SYSTEMATIC_ASSESSMENT", "notes": "Self-reported incident fatigue during 7 days using study medication", "stats": [{"groupId": "EG000", "numEvents": 3, "numAffected": 3, "numAtRisk": 28}, {"groupId": "EG001", "numEvents": 1, "numAffected": 1, "numAtRisk": 28}]}, {"term": "Lightheadedness upon standing", "organSystem": "Vascular disorders", "assessmentType": "SYSTEMATIC_ASSESSMENT", "notes": "Self-reported incident lightheadedness upon standing during 7 days using study medication", "stats": [{"groupId": "EG000", "numEvents": 1, "numAffected": 1, "numAtRisk": 28}, {"groupId": "EG001", "numEvents": 1, "numAffected": 1, "numAtRisk": 28}]}, {"term": "Headache", "organSystem": "General disorders", "assessmentType": "SYSTEMATIC_ASSESSMENT", "notes": "Self-reported incident headache during 7 days while using study medication", "stats": [{"groupId": "EG000", "numEvents": 0, "numAffected": 0, "numAtRisk": 28}, {"groupId": "EG001", "numEvents": 1, "numAffected": 1, "numAtRisk": 28}]}, {"term": "Gastrointestinal discomfort", "organSystem": "Gastrointestinal disorders", "notes": "Self-reported incident gastrointestinal discomfort during the 7 days while using study medication", "stats": [{"groupId": "EG000", "numEvents": 2, "numAffected": 2, "numAtRisk": 28}, {"groupId": "EG001", "numEvents": 2, "numAffected": 2, "numAtRisk": 28}]}, {"term": "Dry eyes", "organSystem": "Eye disorders", "assessmentType": "SYSTEMATIC_ASSESSMENT", "notes": "Self-reported incident dry eyes during 7 days while using study medication", "stats": [{"groupId": "EG000", "numEvents": 1, "numAffected": 1, "numAtRisk": 28}, {"groupId": "EG001", "numEvents": 0, "numAffected": 0, "numAtRisk": 28}]}, {"term": "Reduced exercise tolerance", "organSystem": "General disorders", "assessmentType": "SYSTEMATIC_ASSESSMENT", "notes": "Self-reported incident reduction in exercise tolerance during the 7 days while using study medication", "stats": [{"groupId": "EG000", "numEvents": 0, "numAffected": 0, "numAtRisk": 28}, {"groupId": "EG001", "numEvents": 1, "numAffected": 1, "numAtRisk": 28}]}]}, "moreInfoModule": {"certainAgreement": {"piSponsorEmployee": false, "restrictiveAgreement": false}, "pointOfContact": {"title": "Dr. Scott Sands", "organization": "Brigham and Women's Hospital", "email": "sasands@bwh.harvard.edu", "phone": "617 278 0911"}}}, "derivedSection": {"miscInfoModule": {"versionHolder": "2024-06-24"}, "conditionBrowseModule": {"meshes": [{"id": "D000006333", "term": "Heart Failure"}], "ancestors": [{"id": "D000006331", "term": "Heart Diseases"}, {"id": "D000002318", "term": "Cardiovascular Diseases"}], "browseLeaves": [{"id": "M4361", "name": "Apnea", "relevance": "LOW"}, {"id": "M15694", "name": "Sleep Apnea Syndromes", "relevance": "LOW"}, {"id": "M9421", "name": "Heart Failure", "asFound": "Heart Failure", "relevance": "HIGH"}, {"id": "M9419", "name": "Heart Diseases", "relevance": "LOW"}], "browseBranches": [{"abbrev": "BC08", "name": "Respiratory Tract (Lung and Bronchial) Diseases"}, {"abbrev": "BC23", "name": "Symptoms and General Pathology"}, {"abbrev": "All", "name": "All Conditions"}, {"abbrev": "BC10", "name": "Nervous System Diseases"}, {"abbrev": "BC14", "name": "Heart and Blood Diseases"}]}, "interventionBrowseModule": {"meshes": [{"id": "D000000086", "term": "Acetazolamide"}], "ancestors": [{"id": "D000000927", "term": "Anticonvulsants"}, {"id": "D000002257", "term": "Carbonic Anhydrase Inhibitors"}, {"id": "D000004791", "term": "Enzyme Inhibitors"}, {"id": "D000045504", "term": "Molecular Mechanisms of Pharmacological Action"}, {"id": "D000004232", "term": "Diuretics"}, {"id": "D000045283", "term": "Natriuretic Agents"}, {"id": "D000045505", "term": "Physiological Effects of Drugs"}], "browseLeaves": [{"id": "M2536", "name": "Acetazolamide", "asFound": "Feelings", "relevance": "HIGH"}, {"id": "M4246", "name": "Anticonvulsants", "relevance": "LOW"}, {"id": "M5515", "name": "Carbonic Anhydrase Inhibitors", "relevance": "LOW"}, {"id": "M7951", "name": "Enzyme Inhibitors", "relevance": "LOW"}, {"id": "M7411", "name": "Diuretics", "relevance": "LOW"}], "browseBranches": [{"abbrev": "NaAg", "name": "Natriuretic Agents"}, {"abbrev": "AntiConv", "name": "Anticonvulsants"}, {"abbrev": "All", "name": "All Drugs and Chemicals"}]}}, "hasResults": true}